Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,454.00
(
-1.17%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
105.43
(
1.20%
)
Bitcoin
80,633.81
(
-0.52%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 128945

Friday, 10/21/2011 12:10:35 PM

Friday, October 21, 2011 12:10:35 PM

Post# of 257566
It remains to be seen whether ribavirin will be part of ABT’s all-oral HCV combination, when all is said and done. The components will likely include ABT-450 (a PI), ABT-267 (an NS5A inhibitor), and one of the non-nukes (ABT-072 or ABT-333).

ABT-450 requires boosting with ritonavir, so there are at least four drugs in the cocktail (and possibly five) if you count ritonavir.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today